Tectonic Therapeutics’s Phase Ib results for TX45 in patients with Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) quickly dispelled concerns about potential read-through from another developer’s decision to discontinue its program for a drug in the same class, with particularly impressive results for patients from a more severe subgroup.
Tectonic’s Plates Shift On Positive Phase Ib PH-HFpEF Data
The company announced data that exceeded expectations and prompted a jump in its stock price shortly after its shares plunged on news of a related Lilly drug’s discontinuation.
More from Cardiovascular
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.
• By
Chairman Antoine Papiernik spoke to Scrip about the therapeutic areas that where the VC major is looking at to invest its considerable cash pile.
• By
Battling AstraZeneca in the aldosterone inhibitor space, Mineralys reports Phase III data showing lorundrostat can significantly decrease uncontrolled/resistant blood pressure at six weeks.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.